Ken Griffin Rain Therapeutics Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.22 $23,290 - $33,826	27,727 Added 3629.19%	28,491 $34,000
Q3 2023 Nov 14, 2023	BUY	$0.82 - $1.42 $626 - $1,084	764 New	764 $0
Q1 2023 May 15, 2023	SELL	$7.77 - $12.47 $170,535 - $273,691	-21,948 Reduced 68.32%	10,175 $88,000
Q4 2022 Feb 14, 2023	SELL	$5.52 - $8.48 $193,901 - $297,876	-35,127 Reduced 52.23%	32,123 $256,000
Q3 2022 Nov 14, 2022	BUY	$4.75 - $8.01 $270,218 - $455,672	56,888 Added 549.01%	67,250 $328,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.